Particle.news
Download on the App Store

PCOS Officially Renamed Polyendocrine Metabolic Ovarian Syndrome

The new label aims to move care from cysts to whole‑person screening across metabolic plus mental health.

Overview

  • An international consensus group led by Monash University researchers announced the PMOS name this month after a 14‑year process that gathered input from thousands of patients and clinicians.
  • PMOS describes a multisystem hormone disorder that can affect periods, skin, weight, fertility, blood sugar, heart health, sleep, and mood rather than a cyst problem alone.
  • Current clinical guidance cited in coverage says adults are diagnosed when at least two findings are present: irregular or absent ovulation, elevated androgens or their symptoms, or polycystic ovaries on ultrasound or high anti‑Müllerian hormone.
  • Researchers and clinicians expect a multiyear transition to update guidelines, education, and disease classification, with a push for earlier checks for insulin resistance, diabetes risk, cholesterol, blood pressure, sleep issues, and mental health.
  • The scale is large, with WHO estimates of 10% to 13% of women of reproductive age affected and reports of up to 70% going undiagnosed, which leaves many without timely care for treatable symptoms.